Adial Pharmaceuticals, Inc. (ADIL) announced Tuesday that Purnovate, Inc., a subsidiary of Adial, achieved positive in-vivo data from its study with mice treated with Purnovate's PNV-6005 as a potential treatment for inflammatory bowel diseases.
PNV-6005 is a selective adenosine 2A receptor agonist designed to have anti-inflammatory properties and protective effects against colitis and other inflammatory bowel diseases (IBD).
In the study, PNV-6005 demonstrated statistically significant effect against both primary study endpoints, which are pre-clinical endpoints expected to indicate potential efficacy against ulcerative colitis in humans.
Specially, PNV-6005 significantly prevented weight loss as compared to the control group (greater than 50% inhibition of weight loss). It also significantly prevented colon damage as evidenced by reduction of shortening of colon lengths in the PNV-6005 treated group (almost total prevention), as well as a decrease in inflammation as assessed histologically.
For comments and feedback contact: editorial@rttnews.com
December 12, 2025 15:14 ET Central bank decisions dominated the economic news flow this week led by the Federal Reserve. Trade data from the U.S. also gained attention. The Canadian and Swiss central banks also announced their interest rate decisions. Inflation data from China was in focus as the country released the latest consumer price and producer price data.